Loading clinical trials...

Health-Related Quality of Life Among Patients With Inflammatory Bowel Disease | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATION

Health-Related Quality of Life Among Patients With Inflammatory Bowel Disease

Health-Related Quality of Life and Associated Factors Among Patients With Inflammatory Bowel Disease: Cross-Sectional Multicentre Study

NCT07436910•Cairo University

View on ClinicalTrials.gov

Summary

The primary aim of this study is to assess HRQOL and its associated factors among people with IBD. The target sample will be 385 adult patients diagnosed with IBD (both Crohn's Disease and Ulcerative Colitis). The data will be collected using a self-administered survey.

Detailed Description

The target population will be adult patients diagnosed with IBD. Participants will receive full information about the study's purpose, the voluntary nature of their participation, and the complete confidentiality of their data, including the right to withdraw at any point without explanation. Informed written consent will be obtained from each participant before they complete the questionnaires. Collected data will be stored securely on a password-protected computer and anonymized through coding. Descriptive and inferential statistics will be used to analyze the data.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years or older.
•Have a confirmed diagnosis of IBD.
•Can understand and complete the study questionnaires.
•Provide written informed consent to participate in the study.

Exclusion Criteria

•Have a diagnosis of indeterminate colitis.
•Have any other chronic inflammatory conditions.
•Have severe cognitive impairment that hinders their ability to complete the questionnaires.

Locations (1)

Cairo University

Cairo, Egypt

Key Dates

Start Date

September 1, 2025

Primary Completion Date

June 30, 2026

Completion Date

December 30, 2026

Last Updated

February 27, 2026

Enrollment

385

ESTIMATED participants

Conditions

Irritable Bowel DiseaseUlcerative Colitis (UC)Crohn Disease (CD)

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07271069

Ulcerative Colitis (UC)

View study

RECRUITING

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Health-Related Quality of Life Among Patients With Inflammatory Bowel Disease

Inclusion Criteria

Exclusion Criteria

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Desloratadine in Patients With Ulcerative Colitis

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients